Background: Various errors in the design, conduct, and analysis of medical and public health research studies can produce false results and waste valuable resources. While systematic reviews and meta-analyses are arguably considered the most dependable source of evidence-based medicine, increasing numbers of studies are indicating that, on the contrary to the public's belief, many of these investigations are redundant, erroneous, and even biased.
Introduction
The number of meta-analyses published annually is increasing rapidly with each year. Systematic reviews and meta-analyses are generally considered to be highest in the hierarchy of evidence-based medicine, mainly because of a greater statistical power with which to identify meaningful findings that are not evident in individual studies; to discover methodological flaws, redundancies, and sources of heterogeneity in current medical literature; and to provide direction for future research and policymakers [1] . Ironically, however, multiple investigators have previously found metaanalyses, which should arguably be the most dependable source of evidence-based medicine, to be redundant [2] , erroneous [3] [4] [5] [6] [7] [8] [9] [10] [11] , and even biased [10] . Concerning errors, reports have raised questions in regard to data extraction errors [3, 4, 11] , unit of analysis errors [5] , calculation errors [9] , and misclassification errors [10] . Some of these errors have been found to seriously undermine previously published results in several studies [4, 7, 8, 10] . The mere existence of these errors poses serious threats to the medical community, as many of the results published in academic journals are directly translated to clinical practice [6] .
Recently, genetic epidemiology studies on cancer have dramatically increased in number. The tremendous increase in genetic association studies, including genome-wide association studies (GWAS), has raised concerns for the quality of various genomewide association meta-analyses [12] . However, very few studies have examined the 'error phenomenon' in the field of genetic epidemiology. Although there were some studies on biases in metaanalysis of genetic association studies [13, 14] or on the question as to whether the genotype-phenotype association result can be reproduced [15, 16] , not a single study has yet examined the rate of redundancies in the initial design of research, failure to reference previous works and computational errors such as using the wrong model and inaccurate case and control numbers, especially in the meta-analysis of genetic association studies. Here, we report on a systematic investigation of genetic association metaanalyses addressing microRNA gene-variants and risk of cancer. We not only examine the nature of redundancies in genetic epidemiology research but also discuss various errors found in meta-analyses and the common practice of neglecting to reference previous studies. Moreover, we also discuss how these practices affect the significance of the meta-analysis results and provide practical recommendations in hopes of improving the conduct of future genetic association meta-analyses.
Materials and methods
We carried out a PubMed search until 15 August 2016 using the search terms microRNA, miRNA, polymorphism, gene, genetic variation, and meta. Meta-analyses that (i) were written in English, (ii) investigated cancer risks in terms of odds ratio (OR) and 95% confidence intervals (CI), and (iii) examined associations by cancer sites were included. Studies that were (i) not related to miRNA polymorphism, (ii) published as a letter, editorial comments, or review, and (iii) written on various bioinformatics and statistical methods were excluded. Finally, 94 articles were retained out of the total 403 articles ( Figure 1 ). PROSPERO registration status and the reference list of all 94 studies were screened. Reference status was categorized as 'cited', 'described', and 'discussed' and the definitions for these terms are listed in supplementary Table S4 , available at Annals of Oncology online.
Data (e.g. publication date, number of studies, ethnicity, model, number of case and controls, bias, etc.) were extracted from each metaanalysis, and associations with P-value < 0.05 were considered to be statistically significant. In this paper, an 'association' refers to the relationship between one microRNA polymorphism or gene variant and one type of cancer (e.g. miR-149/rs2292832 and breast cancer). Likewise, herein, a genotype comparison refers to one particular model of an association (e.g. miR-149/rs2292832 and breast cancer C versus T).
During data extraction, we identified multiple overlapping meta-analyses that investigated identical studies. Here, overlapping meta-analyses refer to meta-analyses that used the same published case-control studies to generate the same outcome with the exact same population sample (i.e. case and control) size as well (OR, 95% CI, P-value). Updated meta-analyses that investigated the same association using more recently published case-control studies in addition to the case-control studies used by a previous metaanalysis and meta-analyses that investigated the same association using different combinations of previous case-control studies together were referred to as non-overlapping meta-analyses.
Out of the 94 articles that were selected, 54 articles were found to be overlapping meta-analyses. In terms of associations, out of the 217 associations that were investigated by 94 articles, 80 associations from 54 articles were overlapping. Here, overlapping associations refer to associations that were analyzed using the same population sample size to generate the same outcome; however, the types of genotype comparison or model analyzed in the same association may be different by investigator (results on the variation in genotype comparison analysis are shown in supplementary Tables S8 and S9 , available at Annals of Oncology online). We critically examined these overlapping meta-analyses by comparing their number of studies, number of cases and controls, models, and odds ratios.
Out of 54 overlapping meta-analyses, nine meta-analyses referenced previous overlapping meta-analyses. Using these nine meta-analyses, we also compared PICO (participants, intervention, comparator, and outcome) questions between referencing and referenced meta-analyses and calculated the similarity score (supplementary Table S5 , available at Annals of Oncology online) [17] . Quality of the referencing meta-analysis was measured via AMSTAR (a measurement tool for the assessment of the methodological quality of systematic reviews), which is a reliable and practical instrument designed to help end-users discriminate between systematic reviews with a focus on quality of reporting and conduct [18] . Multivariable binary logistic regression analysis via STATA 12.0 (Stata Corp, College Station, TX) was used to examine potential predictors of citing, describing, and discussing previous meta-analyses in the referencing meta-analyses. Article specific predictors, such as journal impact factor (based on Journal Citation Records, 2014 edition), publication year, concordance of results, similarity of review questions and AMSTAR score, were also analyzed. During the multivariable binary logistic regression analysis, three linear regressions were fitted between one of the three outcomes or dependent variables (citing, describing, and discussing previous meta-analyses in the referencing meta-analyses) and five independent variables (journal impact factor, publication year, concordance of results, similarity of review questions and AMSTAR score). The matrix used for the logistic regression is also included in the supplementary File, available at Annals of Oncology online (supplementary Table S12 , available at Annals of Oncology online).
While analyzing these overlapping meta-analyses, we noticed several meta-analyses with inconsistent results. We tried reproducing these results via Review Manager 5.3 (Cochrane Collaboration, Oxford, UK) [19] and recorded reasons for their discrepancies. We then computed the false positive report probability (FPRP), which is the 'probability of no association given a statistically significant finding' and is analogous to 1 minus the predictive value of a positive test, for the statistically significant associations using the methods and excel spreadsheet provided by Wacholder et al. [20] Calculation of FPRP requires the statistical power of the test, observed P-value, and a given prior probability for the association. Herein, statistical power to detect an OR of 1.1 and 1.5 as recommended by Wacholder et al. [20] , tabulated P-values of significant associations, and two levels of prior probabilities at 0.001 and 0.000001, which are what would be expected for a candidate gene and a random single nucleotide polymorphism, respectively, were used [21] . In the case of the statistical power, though Wacholder et al. [20] previously recommended using statistical power to detect an OR of 1.5 with a-level equal to the observed P-value, we considered this estimate to be too conservative and thus decided to also include results for the median OR of 1.1 as well. Associations with FPRP <0.2 were considered 'noteworthy' as suggested in [20] . Lastly, we created a guideline for conducting and updating meta-analyses in the future (Figure 2 ).
Results

Overlapping meta-analyses
Among the 217 miRNA gene-variant cancer associations reported by 94 published meta-analyses (supplementary Table S1 , available at Annals of Oncology online), 80 (37%) associations had overlapping results. Many of these outcomes, however, were reported by different authors either in different journals or, in some instance, in the same journals at a later publication date. More importantly, not a single overlapping meta-analysis was registered into PROSPERO (supplementary Table S2 , available at Annals of Oncology online). However, this was also the case for non-overlapping meta-analyses, among which only one study was ever registered (supplementary Table S1 , available at Annals of Oncology online).
Nonetheless, as expected, the above overlapping results were more frequent in common cancers, as reported by the American Cancer Society and the National Cancer Institute, USA, such as breast cancer (n ¼ 20), colorectal cancer (n ¼ 16), and lung cancer (n ¼ 13). However, even in a less frequent cancer, such as prostate cancer, the reported results from all four studies overlapped [22] [23] [24] [25] . A list of all data regarding the 80 overlapping associations is available in supplementary Table S2 , available at Annals of Oncology online. Out of the total 80 overlapping associations, 71 (89%) associations should have had references because there were previously published meta-analyses that used the same case-control studies (supplementary Table S3 , available at Annals of Oncology online). The other 9 (11%) associations did not require references because either there were no previously published articles at an earlier publication date or only one metaanalysis ever evaluated the particular miRNA gene-variant cancer association up to our search date.
Twenty-two of 71 (31%) overlapping associations referenced previous meta-analyses. Among these 22 associations, only 8 (36%) associations from nine meta-analyses referenced overlapping results with the meta-analyses of other 14 (64%) associations referencing meta-analyses that pooled the data either from an incomplete list or from a different combination of case-control studies.
As shown in Table 1 , the above 9 meta-analyses for the 8 overlapping associations referenced a total of 31 earlier meta-analyses with overlapping results. As expected, out of these 31 possible references, 23 (74%) were cited, 12 (39%) were described, and 5 (16%) were discussed. The summary characteristics of referenced meta-analyses by the 9 meta-analyses of 8 overlapping associations are summarized in supplementary Table S6 , available at Annals of Oncology online.
In addition, the multivariable binary logistic regression analysis indicated that describing a previous overlapping meta-analysis by the most recent overlapping meta-analysis was positively associated with impact factor (OR, 5.75; 95% CI, 1.03-32.02) and AMSTAR score of the most recent meta-analysis (OR, 3.97; 95% CI, 1.23-12.85). Similar results regarding AMSTAR score, however, were not obtained for citing (OR, 1.19; 95% CI, 0.48-2.95) and for discussing (OR, 0.41; 95% CI, 0.09-1.86) a previous overlapping meta-analysis. Furthermore, the impact factor, publication year, concordance of the results, and similarity score of the more recent meta-analyses were not significantly associated with citing, describing, and discussing previous meta-analyses (supplementary Table S7 , available at Annals of Oncology online).
Lastly, analysis of the types of genotype comparisons that were studied for each overlapping association in the overlapping metaanalysis showed that only 30 (38%) overlapping associations out of the total 80 overlapping associations were analyzed for all five possible genotype comparisons or models (i.e. allelic frequency, heterozygous, homozygous, dominant, and recessive model) (supplementary Table S8 , available at Annals of Oncology online). We defined a meta-analysis to be 'complete' if all five possible genotype comparisons were analyzed by the author and, though more than five models can analyzed when considering various permutations and interactions with other genes, only five models were analyzed at maximum in all of the meta-analyses analyzed in our study, and thus herein we considered the analysis of only five genotype comparisons to be 'complete'. Genotype comparison analysis of the remaining 50 overlapping associations was found incomplete wherein homozygous model (78%), recessive model (73%), and dominant model (69%) were examined in decreasing order. However, this trend was similar in the overall metaanalyses investigating microRNA-variants in cancer with 72 (33%) associations out of the total 217 associations having analyzed for all 5 genotype comparisons and the rest being analyzed for homozygous (65%), dominant (61%), allelic frequency (58%) model in decreasing order (supplementary Table S9 , available at Annals of Oncology online).
Reproducibility of the overlapping meta-analyses. In addition to the above redundancies, out of the total 80 overlapping miRNA gene-variants associations, 21 (26%) associations showed discordant results despite extracting the outcome from identical case-control studies (Tables 2 and 3 ) and could not be reproduced by our own meta-analyses. Indeed, a total of 60 genotype comparisons for 21 different miRNA gene-variant cancer associations had non-reproducible overlapping results ( Table 2 ). These non-reproducible overlapping associations were present across all cancer sites, except for gastric cancer ( Table 2 ). While 20 (33%) of the above 60 genotype comparisons were assigned with ORs with a discrepancy greater than 0.1, 9 (15%) genotype comparisons had ORs with a discrepancy greater than 0.25, compared with our recalculated values.
Common errors for these discrepancies comprised errors in which the authors used the wrong case and control numbers [24, 26] , incorrectly interpreted the accurate results (i.e. interpreted the result as significant when P-value was <0.05 even though the 95% CI included 1.0 or interpreted non-significant (P-value !0.05) result as significant and vice versa) [24, 27, 28] , and analyzed the data under a wrong model [29] (fixed model versus random effect model) (supplementary Table S10 , available at Annals of Oncology online). We reached the conclusion that a wrong model was used when the results reported by the original authors were obtained during the reproduction process wherein both fixed and random effect models were tried. Heterogeneity test was carried out during the reproducibility analysis and the definition of heterogeneity defined by the original meta-analysis was used (i.e. P h < 0.05 or I 2 ! 50%, etc.) before choosing either a fixed or random effect model. Overall, the exact reasons for the discrepancies of 47 (78%) genotype comparisons could not be found, and the error was presumed to be within the data extraction. Fourteen (26%) out of the 54 genotype comparisons for 5 different miRNA gene-variant cancer associations had partial data extraction errors, meaning that only few out of the entire models that were analyzed were non-reproducible. Likewise the remaining 40 (74%) genotype comparisons had complete data extraction errors wherein the results of every model analyzed for a particular gene-variant cancer association was nonreproducible. Moreover, one author who published an overlapping meta-analysis at a later publication date reported that the results of eight genotype comparisons that were identified from two previous overlapping meta-analyses were non-reproducible due to data extraction errors (Table 3 ) [30] .
Interestingly, based on the recalculated values, the statistical significance (P-value <0.05) of 30 genotype comparisons changed from either non-significance to significance or vice versa wherein 26 (87%) genotype comparisons were found significant on the contrary to the initial reports of being non-significant (Table 3) . To assess whether any of these missed significant Continued findings were possibly robust, noteworthy associations, we calculated the FPRP value, which is the 'probability of no true association between a genetic variant and disease (null hypothesis) given a statistically significant finding' and is analogous to 1 minus the predictive value of a positive test. Surprisingly, none of these genotype comparisons had FPRP values <0.2 and thus were not considered noteworthy when we calculated statistical power based on the statistical power to detect an OR of 1.1 and 1.5 (sup plementary Table S11 , available at Annals of Oncology online).
Discussion
Our investigation demonstrates that there have been many redundant and overlapping meta-analyses, suggesting increased waste in research design and analysis in recent years. This phenomenon has been around for many years and was reported in multiple studies [54] [55] [56] , although such practice continues to persist. Although overlapping meta-analyses can validate the reliability of a given result, these meta-analyses not only waste efforts by investigators and peer reviewers [56] but also undermine journals' impact factors by making multiple journals compete for citations [55] .
In addition, our finding showed that 16% of the overlapping meta-analyses were published 2 years after the publication year of the earliest overlapping meta-analyses despite consideration of article publication time lag. Publications with the last search date that is at least a year older than the publication date seriously impede the translation of up-to-date evidence into action. Our results suggest that one of the main causes of overlapping meta-analyses is the lack of registration. None of the overlapping meta-analyses was registered into PROSPERO, which is an online public access for registering a study protocol. The likely reasons for such low PROSPERO registration are presumed to be the lack of awareness, fear of an idea being stolen, and barriers in the registration process due to pre-specifications of a protocol.
However, in addition to PROSPERO, many overlapping metaanalyses also neglected to reference previous overlapping studies. Such neglect of previous meta-analyses has been a constant issue in academia [57] and is a serious cause of unnecessary duplications in medical research. Only 43% of the overlapping metaanalyses referenced past studies, the majority of which were mere citations. In such cases, one could argue that simply putting a reference is not enough and that previous studies should either be described or discussed in a meaningful context. We investigated whether neglect to reference a previous study is predicted by several variables. A meta-analysis was found more likely to be described by a recent meta-analysis if it also referenced previous meta-analyses. In fact, the odd of being described by a recent meta-analysis was found to increase by nearly fourfold with increased quality of referencing meta-analyses indicated by the AMSTAR score and by at least fivefold with higher impact factor of referencing meta-analysis. This is expected since studies that efficiently take the advantage of referencing are generally more prone to also have well-defined objectives and strong or interesting corroborative or contrasting results, allowing these papers to generally be accepted by journals of higher impact factor and making these papers also a subject of reference for the next meta- Abbreviations: P, participants; I, interventions; C, comparators/controls; O, outcomes; AMSTAR, assessment of multiple systematic reviews ƒ Overlapping meta-analyses refer to meta-analyses that used the same literatures for analyzing the gene/variant associations for a particular cancer site *Overlapping associations refer to associations that were analyzed using the same population sample size to generate the same outcome; however, the types of genotype comparison or model analyzed in the same association may be different by investigator For column "cited", "described", and "discussed", 1 was assigned when the article was cited/described/discussed by the above meta-analysis. Likewise, 0 was assigned when the article was not cited/described/discussed. For "concordance of results", 0 was assigned when the result of the study was inaccurate and 1 when the result was accurate and in concordance to the recalculated odds ratio, confidence interval, and p-value by our meta-analysis. For "PICO", 1 was assigned when the items were identical and 0 was assigned when the items were different. For "PICO" and "Similarity Score" definitions, see supplementary analysis. Interestingly, such correlation was not found in discussing a previous meta-analysis; however, this correlation is presumed to be difficult to obtain, considering that very few studies included in our analysis were found to have been discussed by overlapping meta-analyses. In addition, low number of independent variables used for the binary logistic regression analysis could have also yielded such poor correlation since it is more difficult for the regressors to be fit. Abbreviations: OR, odds ratio; CI, confidence interval a Overlapping meta-analyses refer to meta-analyses that used the same literatures for analyzing the gene/variant associations for a particular cancer site *Changes refer to changes in statistical significance: significant means that the genotype comparison changed from non-significant to significant and non-significant means that the genotype comparison changed from significant to non-significant. The statistical significance of 32 associations' odds ratio and 95% confidence interval changed after recalculation, out of which 4 (12.5%) were found to be statistically non-significant after recalculation and 28 (87.5%) were found to be statistically significant.
Furthermore, although other forms of referencing, such as citing and discussing a previous meta-analysis, did not correlate with impact factor, publication date, concordance of the results and the similarity score of the referencing meta-analysis in our results, referencing a previous work was reported to be positively associated with some of these factors in a study by Helfer et al. [57] . According to Helfer et al. [57] the odds of being cited by a recent meta-analysis increased for every increase of one unit in impact factor. However, it is important to note that Helfer et al. selected meta-analyses on pharmacological treatments that were published in journals with the highest impact factors. Thus, the discrepancy between our results and that of Helfer et al. [57] can be due to the fact that not only were many of the microRNA gene variant and cancer studies published in journals with lower impact factor but also the authors of the gene variant meta-analyses simply had a low tendency to reference previous work, given such low level of referencing of the overlapping meta-analyses. However, this result should not deter authors from making crucial insights based on previous works simply because the publication is outside high-impact-factor journals or rather refer a previous work based on high visibility than on grounds of methodological validity to publish at a high-impact-factor journal.
Moreover, according to Helfer et al. [57] meta-analyses with different results were found more likely to have been described by a recent meta-analysis; however, such correlation was not found in our analysis. This discrepancy might be due to the fact that we analyzed overlapping meta-analyses that investigated the same case-control studies. However, we also similarly speculate that considering such low levels of referencing, authors may have restrained from revealing similar findings by previous studies to artificially inflate their 'novelty value' during the process of publication. More recently, journals have limited acceptance to papers with novel, cutting-edge results, and thus, obtaining the same results or using similar methodology may be perceived as lacking originality [62] . Although this problem extends beyond the investigator to editors, peer reviewers, and even readers, the investigator is nevertheless not free from altering the current understanding and direction of medical research. Other likely reasons for low levels of referencing can also be that authors did not perform required literature search before their analyses and that the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist does not obligate authors to indicate the conclusions of previous meta-analyses on a given topic [2] . In addition to the redundancies, only one-third of the total number of meta-analyses was found to have analyzed all possible genotype comparisons for each association. This phenomenon was also found to be pervasive among the overlapping metaanalyses. Though the choice of analyzing a particular genotype comparison is up to the investigator, it should be noted that incomplete analyses allow for an excuse for an unnecessary updated meta-analysis examining a different genotype comparison of the same association. Not only does this type of analysis scatter the information of a single association but it wastes time and efforts of both readers and the investigator.
Moreover, nearly a fourth of the overlapping associations had errors, and the study outcomes could not be reproduced by our meta-analyses. Fifteen percent of these associations had serious errors with OR discrepancies of more than 0.25, compared with our recalculated values. This finding suggests that many metaanalyses have lacked considerable attention to small details during data extraction. Although we tried our best to find the cause of the error during reproduction, we regrettably failed in most (78%) of these associations. Details on how the data were extracted were written in very few meta-analyses. Moreover, 50% of the 60 non-reproducible genotype comparisons had their statistical significance changed from non-significance to significance and vice versa following recalculations. Further analysis revealed that 87% of these changes were significant genotype comparisons that were reported to be not significant by initial meta-analyses. Considering the fact that a reproducibility of a work can potentially serve as a minimum standard of assessing the value of a scientific claim [63] , this phenomenon observed in our investigation demonstrates that some levels of improvements in reproducing published results are seriously needed. Consistent with this finding, one author [63] has previously recommended that all investigators conducting any form of computing should publish their data set and code, if applicable, so that field experts may be able to check for errors. Since not all significant genotype comparisons represent true associations, a Bayesian approach using FPRP that considers not only observed P value but also both the power and prior probability of the hypothesis was carried out. FPRP calculations were thus carried out to observe the number of potentially missed, but noteworthy (FPRP <0.2), associations out of the missed significant (P < 0.05) associations. Interestingly, none of the missed associations were found noteworthy, thus one could argue that despite these errors in the meta-analyses, no crucial association was lost. However, considering that no GWAS study was included in the overlapping meta-analyses and only 28 missed significant genotypecomparisons were examined in our analysis, even one missed noteworthy association would have signaled a serious error prevalence of $3.5%. Since results from meta-analyses of GWAS studies generally have lower P-values, ranging below 5 Â 10 À8 in the case of significant studies [64] , under FPRP calculations, more noteworthy associations may be revealed and an error in the meta-analysis of GWAS study is speculated to lead to a fatal mistake. Furthermore, although we analyzed the accuracies of the data only in overlapping associations, our results indirectly suggest that this type of error in data handling is pervasive throughout all meta-analyses regardless of topic. Nevertheless, very few studies have previously reported on data extraction errors in meta-analyses [3, 11] .
To the best of our knowledge, this paper is the largest samplesize meta-analysis to have studied data extraction errors. This paper is also the first to reveal unnecessary duplications, neglect of previous studies, omission of referencing, and erroneous meta-analyses in genetic association studies. Recently, with advances in genotyping technologies, a large amount of data on the location, type, quantity, and prevalence of genetic variations have been reported, and an increasing number of studies are now exploring the significance of these variations in relation to risk of cancers and other diseases. The tremendous amount of attention that has been geared toward genetic studies in the last decade has raised concerns as to how to find a truly significant association in the midst of all the information. While statistical methods, such as the FPRP, have been adopted to reduce the level of noise and identify noteworthy associations, this approach relies on the assumption that all genetic association data that have been previously published are highly accurate.
Our results suggest that the prevalence of errors in the metaanalysis of genetic association studies is higher than would be expected and that this phenomenon may be pervasive throughout all meta-analysis regardless of topic. Although these errors can happen by mistake, they should still be avoided if possible, since they negate or sometimes reverse important findings that are used by all readers, including reviewers and policymakers. Thus, we have included a guideline for updating systematic reviews and meta-analyses for future authors (Figure 2) .
Investigators should strive to reduce unnecessary duplications and sincerely consider whether there is a need to undertake a new project. In the PRISMA checklist, item #3, which asks for the rationale of a review in the context of what is known, authors should strive to explain how their work will add new information to current knowledge and whether this information is new or an update to that of previous work [65] . Investigators should try to take full advantage of referencing to provide readers with a valuable source of information and increase transparency in their studies in order for their results to have greater meaning to a wide range of readers, including not only clinicians and researchers but also policymakers and patients.
